Background Amivantamab-lazertinib significantly prolonged progression-free survival (PFS)
versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant …

Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …

Molecularly targeted therapies have recently expanded the options available for patients
with advanced non-small-cell lung cancer (NSCLC). Two cancer cell pathways in particular …

Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …

Background No targeted therapies are available for KRAS-mutant non-small-cell lung
cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with …

Introduction: Interstitial lung disease (ILD) is an adverse drug reaction (ADR) of concern in
Japanese patients with non–small-cell lung cancer (NSCLC) receiving erlotinib. To …

Abstract Background Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody
that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin …

Introduction: Osimertinib is a third-generation, irreversible, oral epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both …